1. Roufosse F, Weller PF. Practical approach to the patient with hypereosinophilia. J Allergy Clin Immunol. 2010; 126:39–44.
Article
2. Kita H. Eosinophils: multifaceted biological properties and roles in health and disease. Immunol Rev. 2011; 242:161–77.
Article
3. Kobayashi H. Effect of c-kit ligand (stem cell factor) in combination with interleukin-5, granulocyte-macrophage colony-stimulating factor, and interleukin-3, on eosinophil lineage. Int J Hematol. 1993; 58:21–6.
4. Gleich GJ, Loegering DA. Immunobiology of eosinophils. Annu Rev Immunol. 1984; 2:429–59.
Article
5. Acharya KR, Ackerman SJ. Eosinophil granule proteins: form and function. J Biol Chem. 2014; 289:17406–15.
Article
6. Lacy P, Moqbel R. Eosinophil cytokines. Chem Immunol. 2000; 76:134–55.
Article
7. Bullock ED, Johnson EM Jr. Nerve growth factor induces the expression of certain cytokine genes and bcl-2 in mast cells. Potential role in survival promotion. J Biol Chem. 1996; 271:27500–8.
8. Brigden M, Graydon C. Eosinophilia detected by automated blood cell counting in ambulatory North American outpatients. Incidence and clinical significance. Arch Pathol Lab Med. 1997; 121:963–7.
9. Magnaval JF, Laurent G, Gaudré N, Fillaux J, Berry A. A diagnostic protocol designed for determining allergic causes in patients with blood eosinophilia. Mil Med Res. 2017; 4:15.
Article
10. Lowe D, Jorizzo J, Hutt MS. Tumour-associated eosinophilia: a review. J Clin Pathol. 1981; 34:1343–8.
Article
11. Jin JJ, Butterfield JH, Weiler CR. Hematologic malignancies identified in patients with hypereosinophilia and hypereosinophilic syndromes. J Allergy Clin Immunol Pract. 2015; 3:920–5.
Article
12. Williams KW, Milner JD, Freeman AF. Eosinophilia associated with disorders of immune deficiency or immune dysregulation. Immunol Allergy Clin North Am. 2015; 35:523–44.
Article
13. Skiest DJ, Keiser P. Clinical significance of eosinophilia in HIV-infected individuals. Am J Med. 1997; 102:449–53.
Article
14. Kovalszki A, Weller PF. Eosinophilia. Prim Care. 2016; 43:607–17.
Article
15. Tefferi A, Patnaik MM, Pardanani A. Eosinophilia: secondary, clonal and idiopathic. Br J Haematol. 2006; 133:468–92.
Article
16. Webb TA, Li CY, Yam LT. Systemic mast cell disease: a clinical and hema-topathologic study of 26 cases. Cancer. 1982; 49:927–38.
Article
17. Chung J, Nam D, Lee S, Lee E, Hahn J, Ko Y. A clinical study on eosinophilia: with a report of 5 cases of hypereosinophilic syndrome. Korean J Hematol. 1988; 23:127–37.
18. Shin K, Choi Y, Chae S, Hyung S. A clinical study of cause of Eosinophilia. Chungbuk Med J. 1996; 6:105–14.
19. Kim DW, Shin MG, Yun HK, Kim SH, Shin JH, Suh SP, et al. Incidence and causes of hypereosinophilia in the patients of a university hospital. Korean J Lab Med. 2009; 29:185–93.
20. Cacoub P, Musette P, Descamps V, Meyer O, Speirs C, Finzi L, et al. The DRESS syndrome: a literature review. Am J Med. 2011; 124:588–97.
Article
21. Agarwal R, Chakrabarti A, Shah A, Gupta D, Meis JF, Guleria R, et al. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy. 2013; 43:850–73.
Article
22. Cottin V. Eosinophilic lung diseases. Clin Chest Med. 2016; 37:535–56.
Article
23. Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990; 33:1094–100.
Article
24. Prussin C. Eosinophilic gastroenteritis and related eosinophilic disorders. Gastroenterol Clin North Am. 2014; 43:317–27.
Article
25. Simon HU, Rothenberg ME, Bochner BS, Weller PF, Wardlaw AJ, Wechsler ME, et al. Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol. 2010; 126:45–9.
Article
26. Bain BJ. Hypereosinophilia. Curr Opin Hematol. 2000; 7:21–5.
Article
27. Sheikh J, Weller PF. Clinical overview of hypereosinophilic syndromes. Immunol Allergy Clin North Am. 2007; 27:333–55.
Article
28. Yoon SY, Baek S, Park SY, Shin B, Kwon HS, Cho YS, et al. Clinical course and treatment outcomes of toxocariasis-related eosinophilic disorder. Medicine (Baltimore). 2018; 97:e12361.
Article
29. Curtis C, Ogbogu PU. Evaluation and differential diagnosis of persistent marked eosinophilia. Immunol Allergy Clin North Am. 2015; 35:387–402.
Article
30. Kim KM, Bae MH, Kim YM, Cho MJ, Kwak MJ, Kim SH, et al. Cause and incidence of eosinophilia in children: a single center study in one year. Allergy Asthma Respir Dis. 2014; 2:358–61.
Article
31. Lee SP. Hightlights and diagnostic dilemma of toxocariasis. Korean J Med. 2013; 84:200–2.
Article
32. Chen YY, Khoury P, Ware JM, Holland-Thomas NC, Stoddard JL, Gur-prasad S, et al. Marked and persistent eosinophilia in the absence of clinical manifestations. J Allergy Clin Immunol. 2014; 133:1195–202.
Article
33. Adkinson NF, Middleton E. Middleton's allergy: principles and practice. 8th ed.Philadelphia (PA): Elsevier/Saunders;2014.
34. Wu EY, Hernandez ML, Jennette JC, Falk RJ. Eosinophilic granulomatosis with polyangiitis: clinical pathology conference and review. J Allergy Clin Immunol Pract. 2018; 6:1496–504.
Article
35. Rudzińska M, Kowalewska B, Sikorska K. Clinical usefulness of Western blotting and ELISA avidity for the diagnosis of human toxocariasis. Para-site Immunol. 2017; 39.
Article
36. Stone KD, Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol. 2010; 125(2 Suppl 2):S73–80.
Article
37. Bonnin AJ, Montealegre F, Gewurz A. Association of cigarette smoking with elevated serum IgE levels in Hispanic Puerto Rican men. Ann Allergy. 1991; 67:609–11.
38. Arendt JF, Nexo E. Unexpected high plasma cobalamin: proposal for a diagnostic strategy. Clin Chem Lab Med. 2013; 51:489–96.
39. Bochner BS. The eosinophil: For better or worse, in sickness and in health. Ann Allergy Asthma Immunol. 2018; 121:150–5.